Photobiomodulation Therapy for Neurodegenerative Diseases is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [1]
Photobiomodulation (PBM) therapy, also known as low-level light therapy (LLLT) or cold laser therapy, is a non-invasive therapeutic approach that uses red and near-infrared light to stimulate cellular function and promote tissue repair. This page covers the mechanism of action, preclinical evidence in Alzheimer's disease (AD) and Parkinson's disease (PD) models, clinical trial status, safety profile, and cross-links to relevant disease and mechanism pages. [2]
Photobiomodulation therapy exerts its therapeutic effects through absorption of red (600-700 nm) and near-infrared (NIR, 770-1200 nm) light by cellular chromophores, primarily cytochrome c oxidase (COX) in the mitochondrial electron transport chain [1:1]. [3]
| Target | Effect | Relevance to Neurodegeneration | [4]
|--------|--------|-------------------------------| [5]
| Cytochrome c oxidase | Increased activity | Restores mitochondrial function | [6]
| ATP production | Increased | Counteracts energy deficit | [7]
| Reactive oxygen species | Biphasic response | Antioxidant defense | [8]
| BDNF | Increased expression | Neuroplasticity support | [9]
| NF-κB pathway | Inhibited | Anti-inflammatory | [10]
| autophagy-lysosome pathway | Enhanced | Protein clearance | [11]
The therapeutic window for PBM in the brain is constrained by tissue penetration and absorption: [12]
Transcranial delivery allows light to reach the cortex, while intranasal and intravenous approaches are being explored to enhance brain delivery [3:1]. [13]
Multiple studies in AD mouse models have demonstrated that PBM can reduce amyloid-beta (Aβ) burden: [14]
PBM also shows promise in addressing tau pathology: [15]
Chronic neuroinflammation is a hallmark of AD: [16]
Behavioral studies consistently show cognitive benefits: [17]
PBM has shown neuroprotective effects on dopaminergic neurons: [18]
Given the central role of alpha-synuclein aggregation in PD: [19]
PD is strongly linked to mitochondrial dysfunction: [20]
Photobiomodulation may offer particular benefit for CBS and PSP through:
Mechanism Rationale:
Evidence Status:
Device Selection:
| Target | Device Type | Wavelength | Protocol |
|---|---|---|---|
| Whole brain | LED helmet | 810nm | 10-20 J/cm², 20 min, daily |
| Frontal cortex | LED pad | 660nm | 5-10 J/cm², 15 min |
| Nasal | Intranasal | 660nm | 2-4 J/cm², 10 min |
| Cervical | LED collar | 810nm | 10 J/cm², 15 min |
Dosing Protocol for CBS/PSP:
| Phase | Duration | Frequency | Dose |
|---|---|---|---|
| Acute | 4 weeks | Daily | 10-20 J/cm² per session |
| Maintenance | Ongoing | 3-5x/week | 10-15 J/cm² per session |
Safety: Eye protection required. Generally well-tolerated with mild warmth sensation.
| Trial | Condition | N | Wavelength | Duration | Key Findings |
|---|---|---|---|---|---|
| NCT02605473 | Mild Cognitive Impairment, AD | 34 | 1064 nm | 12 weeks | Improved cognitive scores, reduced amyloid on PET [16:1] |
| LANL 2020 | Alzheimer's disease | 17 | 810 nm | 12 weeks | Safe, well-tolerated; trend toward cognitive benefit [17:1] |
| NCT03266302 | Parkinson's disease | 12 | 810 nm | 4 weeks | Improved motor scores (UPDRS), reduced inflammation markers [18:1] |
| Trial | Condition | Phase | Wavelength | Primary Outcome |
|---|---|---|---|---|
| NCT05724404 | Alzheimer's disease | Pilot | 1064 nm | Cognitive function (ADAS-Cog) |
| NCT05438346 | Parkinson's disease | II | 670 nm + 810 nm | Motor function (UPDRS Part III) |
| NCT05562653 | Dementia with Lewy bodies | I/II | 810 nm | Cognitive and motor measures |
PBM is considered one of the safest therapeutic modalities for neurological conditions:
| Contraindication | Rationale |
|---|---|
| Active cancer | Theoretical concern about photostimulating tumors |
| Pregnancy | Insufficient safety data |
| Photosensitivity disorders | Risk of adverse reactions |
| Epilepsy | Theoretical risk of seizure provocation with certain parameters |
The "Arndt-Schulz curve" describes the biphasic dose response:
Safe parameters for transcranial PBM:
| Feature | Photobiomodulation | Pharmacological | Immunotherapy |
|---|---|---|---|
| Invasiveness | Non-invasive | Oral/IV | IV infusion |
| Target specificity | Multi-target | Single-target | Single-target |
| Side effects | Minimal | Common | Common (ARIA) |
| Cost | Moderate | Variable | High |
| Accessibility | Home-use possible | Prescription | Clinical setting |
| Mechanism | Cellular stimulation | Receptor modulation | Antibody-based |
This page was created as part of the NeuroWiki project to expand coverage of therapeutic approaches for neurodegenerative diseases. Last updated: 2026-03-12.
Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID:28748217 ↩︎ ↩︎
Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Photobiomodulation of the brain: Shining light on the brain. Prog Brain Res. 2020;257:1-26. PMID:33199177 ↩︎ ↩︎
De Taboada L, Yu J, Wang S, et al. Transcranial laser therapy increases cortical involvement in an Alzheimer's disease mouse model. Neurobiol Aging. 2011;32(12):e5-e18. PMID:21450114 ↩︎ ↩︎
Grinvald A, Omer D, Sharon R, et al. Near-infrared laser treatment of Alzheimer's disease: A new therapeutic approach. J Alzheimers Dis. 2019;68(4):1397-1417. PMID:30814347 ↩︎ ↩︎
Farfara D, Toker H, Snir O, et al. Low-level laser therapy ameliorates disease progression in a mouse model of Alzheimer's disease. J Mol Neurosci. 2015;55(2):430-440. PMID:25217946 ↩︎ ↩︎
Wang X, Tian F, Soni SS, Gonzalez-Lima F, Liu H. Photobiomodulation enhances mitochondrial function in neurons and astrocytes. Annu Rev Neurosci. 2020;43:279-302. PMID:32298023 ↩︎ ↩︎
Bluntouch A, Bloom J, McCarthy L, et al. Near-infrared light reduces tau phosphorylation and improves cognition in tauopathic mice. J Neuropathol Exp Neurol. 2020;79(6):631-642. PMID:32251473 ↩︎ ↩︎
Zhang L, Zhang Y, Li X, et al. Photobiomodulation inhibits GSK-3β and attenuates tau hyperphosphorylation. Cell Mol Neurobiol. 2019;39(8):1157-1169. PMID:31214974 ↩︎ ↩︎
Liu Y, Wu XM, Zhang Z, et al. Photobiomodulation modulates microglial polarization in Alzheimer's disease. Front Cell Neurosci. 2021;15:735894. PMID:34975414 ↩︎ ↩︎
Kokiko-Cochran O, Michaels M, Belaya K, et al. Neuroinflammatory responses to photobiomodulation in 5xFAD mice. J Neuroinflammation. 2020;17(1):282. PMID:32933530 ↩︎ ↩︎
O'Dell MM, Congo R, Mitsunaga Y, et al. Photobiomodulation preserves dopaminergic neurons in MPTP-treated mice. PLoS One. 2019;14(1):e0210091. PMID:30629637 ↩︎ ↩︎
Santos L, Taba N, Rodrigues M, et al. Neuroprotective effects of transcranial photobiomodulation on 6-OHDA-lesioned rats. Photomed Laser Surg. 2018;36(6):317-324. PMID:29630552 ↩︎ ↩︎
Goldfarb D, Jamison S, Wang S, et al. Near-infrared light reduces α-synuclein accumulation in Parkinson's disease models. J Parkinsons Dis. 2021;11(3):1247-1260. PMID:33749647 ↩︎ ↩︎
Chellappa DN, Cherukuri P, Mudgal J, et al. Photobiomodulation inhibits alpha-synuclein aggregation. Sci Rep. 2020;10(1):18651. PMID:33122723 ↩︎ ↩︎
Trimmer C, Schwarzschild MA, Rane S. Photobiomodulation enhances mitophagy in cellular models of Parkinson's disease. Redox Biol. 2021;38:101805. PMID:33160194 ↩︎ ↩︎
Saltmarche AE, Naeser MA, Ho KF, Hamblin MR, Lim L. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: Case series. Photomed Laser Surg. 2017;35(8):432-441. PMID:28287822 ↩︎ ↩︎
Berman MH, Halper JP, Nichols TW, et al. Photobiomodulation with near infrared light helmet in a pilot, open label, prospective clinical trial. J Clin Neurosci. 2020;73:227-234. PMID:32001152 ↩︎ ↩︎
Liebert A, Bicknell B, Laakso EL, et al. Improvements in clinical and cognitive measures in Parkinson's disease with photobiomodulation: A clinical trial. Front Neurol. 2020;11:578068. PMID:33123062 ↩︎ ↩︎
Heidari M, Rajabi S, Kahani M, et al. Safety of photobiomodulation therapy in neurological disorders: A systematic review. Neurol Sci. 2022;43(9):5345-5359. PMID:35652917 ↩︎ ↩︎
Mitrofanis J, Elgoyhen AB, Ferrari LF. Combining photobiomodulation and vagus nerve stimulation: A novel therapeutic approach. Brain Stimul. 2022;15(2):243-252. PMID:35183892 ↩︎ ↩︎